<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550237</url>
  </required_header>
  <id_info>
    <org_study_id>2011/710</org_study_id>
    <nct_id>NCT01550237</nct_id>
  </id_info>
  <brief_title>Curative Image Guided Radiotherapy for Prostate Cancer</brief_title>
  <acronym>RIC</acronym>
  <official_title>A Randomised, Two Centre Trial on Daily Cone-beam vs Standard Weekly Orthogonal Image Guided Radiotherapy (IGRT) for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical importance of cone beam computer tomography based image guided radiotherapy (CT-
      IGRT) has not been established. The primary aim of the present trial is to investigate
      whether CT- IGRT and consequently reduced safety margins reduces the rectal side effects from
      curative, high dose radiotherapy in prostate cancer. Any impact of the reduced planning
      target volume in the CT- IGRT arm on biochemical freedom from disease will be evaluated as
      secondary outcome.

      An open randomised phase III trial. The included men will be randomised to receive curative
      radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and
      standard safety margins (10-15 mm) or 78 Gy in 39 fractions with daily CT position
      verification and reduced safety margins (7mm).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute rectal side effects</measure>
    <time_frame>10 weeks</time_frame>
    <description>FWUO94</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from biochemical failure</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer specific survival</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late genitourinary and rectal side effects</measure>
    <time_frame>up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute genitourinary side effects</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>up to 10 years</time_frame>
    <description>HRQoL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">260</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>radiotherapy daily reduced</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>radiotherapy, with daily CT position verification and reduced safety margins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiotherapy weekly standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiotherapy, with weekly orthogonal position verification and standard safety margins</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy daily verification reduced safety margins</intervention_name>
    <description>curative radiotherapy to 78 Gy in 39 fractions with daily CT position verification and reduced safety margins (7mm)</description>
    <arm_group_label>radiotherapy daily reduced</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy weekly verification standard safety margins</intervention_name>
    <description>curative radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm)</description>
    <arm_group_label>radiotherapy weekly standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy confirmed adenocarcinoma of prostate

          -  No evidence of nodal or distant metastases (N0M0)

          -  Intermediate or high risk based on T stage, PSA level and Gleason score

          -  Informed consent

        Exclusion Criteria:

          -  Previous treatment for cancer last 5 years, except basal cell carcinoma of skin

          -  Any previous radiotherapy, except KV or electron treatment of skin tumors outside the
             pelvis

          -  Metallic hip joint replacement

          -  Pre-existing intestinal or genitourinary disease with increased risk of side effects

          -  Any pre-existing condition making the patient unsuitable for radiotherapy

          -  Any pre-existing condition making the patient unsuitable for hormonal therapy

          -  Any pre-existing condition making the patient unsuitable for MRI.

          -  ALAT, GT, ALP, creatinin &gt; 1.5 x upper normal limit
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jo Å Lund, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Olavs Hospital, University Hospital, Trondheim, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ålesund Sykehus</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Tøndel H, Lund JÅ, Lydersen S, Wanderås AD, Aksnessæther B, Jensen CA, Kaasa S, Solberg A. Radiotherapy for prostate cancer - Does daily image guidance with tighter margins improve patient reported outcomes compared to weekly orthogonal verified irradiation? Results from a randomized controlled trial. Radiother Oncol. 2018 Feb;126(2):229-235. doi: 10.1016/j.radonc.2017.10.029. Epub 2018 Feb 3.</citation>
    <PMID>29398152</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiotherapy, image-guided</keyword>
  <keyword>adverse effects</keyword>
  <keyword>position verification</keyword>
  <keyword>safety margins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

